Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lysergic acid diethylamide D-tartrate
- Development stage
- Phase 3
- Lead developer
- MindMed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lysergic acid diethylamide D-tartrate is the tartrate salt form of the semi-synthetic psychedelic compound D-lysergic acid diethylamide (LSD), which is derived from ergot alkaloids. It functions as a potent agonist at multiple G protein-coupled receptors, with its primary psychedelic effects mediated through the 5-hydroxytryptamine receptor 2A (5-HT2A). Beyond serotonin receptors, it also interacts with dopamine and adrenergic receptors. Historically developed by Sandoz and marketed as Delysid for psychiatric research, the compound is currently undergoing a resurgence in clinical development. Modern pharmaceutical companies, such as MindMed (developing it as MM-120), are investigating its efficacy in treating generalized anxiety disorder, major depressive disorder, and other treatment-resistant psychiatric conditions. The D-tartrate salt is preferred in pharmaceutical applications due to its crystalline stability and solubility.
- Brand names
- Delysid
- Other names
- lysergide tartrateD-LSD tartratelysergic acid diethylamide bitartrate(+)-lysergic acid diethylamide tartrate
02
Targets
HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)DRD2 (Dopamine D2 Receptor)HTR2C (5-hydroxytryptamine 2C receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on lysergic acid diethylamide D-tartrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lysergic acid diethylamide D-tartrate.